{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:39:31Z","timestamp":1794854371270,"version":"4.9.1"},"reference-count":106,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.parkreldis.2010.05.004","type":"journal-article","created":{"date-parts":[[2010,6,11]],"date-time":"2010-06-11T06:52:46Z","timestamp":1276239166000},"page":"553-560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"title":["Parkinson\u2019s disease psychosis 2010: A review article"],"prefix":"10.1016","volume":"16","author":[{"given":"Joseph H.","family":"Friedman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2010.05.004_bib1","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib2","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00415-005-0918-5","article-title":"Psychotic symptom in Parkinson\u2019s disease. From description to etiology","volume":"252","author":"Papapetropoulos","year":"2005","journal-title":"J Neurol"},{"issue":"Pt\u00a04","key":"10.1016\/j.parkreldis.2010.05.004_bib3","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/brain\/123.4.733","article-title":"Hallucinations in Parkinson\u2019s disease: prevalence, phenomenology and risk factors","volume":"123","author":"Fenelon","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/01.wnf.0000180228.77802.32","article-title":"Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments","volume":"28","author":"Chou","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib5","first-page":"419","article-title":"Hallucinations Parkinson\u2019s disease clinical syndrome","volume":"80","author":"Goetz","year":"1999","journal-title":"Adv Neurol"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib6","first-page":"494","article-title":"Pharmacology of hallucinations induced by long-term therapy","volume":"129","author":"Goetz","year":"1982","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib7","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/mds.21382","article-title":"Diagnostic criteria for psychosis in Parkinson\u2019s disease: report of an NIND, NIMH work group","volume":"22","author":"Ravina","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib8","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00002826-199108000-00001","article-title":"The management of the levodopa psychoses","volume":"14","author":"Friedman","year":"1991","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib9","series-title":"Comprehensive textbook of psychiatry","author":"Sadock","year":"2000"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1212\/01.WNL.0000148479.10865.FE","article-title":"Hallucinations and sleep disorders in Parkinson\u2019s disease: six-year prospective longitudinal study","volume":"64","author":"Goetz","year":"2005","journal-title":"Neurol"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jns.2009.08.014","article-title":"Epidemiology of psychosis in Parkinson\u2019s disease","volume":"289","author":"Fenelon","year":"2010","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib12","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(05)70146-0","article-title":"Visual hallucinations in the diagnosis of idiopathic Parkinson disease: a retrospective autopsy study","volume":"4","author":"Williams","year":"2005","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1212\/01.wnl.0000191325.31068.c4","article-title":"Hallucinations in Parkinson\u2019s disease in the pre-levodopa era","volume":"66","author":"Fenelon","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib14","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","article-title":"Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium","volume":"65","author":"McKeith","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.parkreldis.2008.11.013","article-title":"Non-motor symptoms in a prevalent population with Parkinson\u2019s disease in Tanzania","volume":"15","author":"Dotchin","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib16","unstructured":"Parant [cited in 17]."},{"key":"10.1016\/j.parkreldis.2010.05.004_bib17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nrneurol.2009.62","article-title":"Hallucinations in Parkinson disease","volume":"5","author":"Diederich","year":"2009","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib18","series-title":"Paralysis agitans. A clinical and genetic study","author":"Mjones","year":"1949"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib19","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.parkreldis.2008.07.004","article-title":"Dopamine agonists in the treatment of early Parkinson disease: a meta analysis","volume":"15","author":"Baker","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib20","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/brain\/awf033","article-title":"Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe","volume":"125","author":"Harding","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib21","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/gps.389","article-title":"A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson\u2019s disease with and without dementia","volume":"16","author":"Aarsland","year":"2001","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib22","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1600-0404.2007.00860.x","article-title":"Clinical evaluation of Parkinson\u2019s disease dementia: association with ageing and visual hallucinations","volume":"116","author":"Kitayama","year":"2007","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1212\/WNL.55.2.281","article-title":"Hallucination, REM sleep, and Parkinson\u2019s disease: a medical hypothesis","volume":"55","author":"Arnulf","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/mds.22919","article-title":"Visual hallucinations and altered visual information processing in Parkinson disease and dementia with Lewy bodies","author":"Kurita","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib25","article-title":"Differential progression of brain atrophy in Parkinson disease with and without visual hallucinations","author":"Ibarretxe-Bilbao","year":"2009","journal-title":"J Neuorol Neurosurg Psychiatr"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib26","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1093\/brain\/awp223","article-title":"Impaired visual processing preceding image recognition in Parkinson\u2019s disease patient with visual hallucinations","volume":"132","author":"Meppelink","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib27","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1136\/jnnp.70.6.734","article-title":"Prospective study of hallucinations and delusions in Parkinson\u2019s disease","volume":"70","author":"Holroyd","year":"2001","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib28","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.parkreldis.2008.05.007","article-title":"Dementia and visual hallucinations asociated with limbic pathology in Parkinson\u2019s disease","volume":"15","author":"Kalaitzakis","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib29","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/mds.21875","article-title":"Scales to assess psychosis in Parkinson\u2019s disease","volume":"23","author":"Fernandez","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1212\/01.WNL.0000148479.10865.FE","article-title":"Hallucinations and sleep disorders in Parkinson\u2019s disease: six-year prospective longitudinal study","volume":"64","author":"Goetz","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib31","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/archneur.63.5.713","article-title":"The malignant course of \u201cbenign hallucinations\u201d in Parkinson\u2019s disease","volume":"63","author":"Goetz","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.parkreldis.2005.06.011","article-title":"Caregiver-burden in parkinson\u2019s disease is closely associated with psychiatric symptoms, falls, and disability","volume":"12","author":"Schrag","year":"2006","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib33","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1212\/WNL.43.11.2227","article-title":"Risk factors for nursing home placement in advanced Parkinson\u2019s disease","volume":"43","author":"Goetz","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib34","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1212\/WNL.45.4.669","article-title":"Mortality and hallucinations in nursing home patients with advanced Parkinson\u2019s dissase","volume":"45","author":"Goetz","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib35","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","article-title":"Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease","volume":"340","author":"Parkinson Study Group","year":"1999","journal-title":"N Engl J Med"},{"issue":"3 Pt 1","key":"10.1016\/j.parkreldis.2010.05.004_bib36","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1212\/WNL.44.3_Part_1.544","article-title":"Clozapine: a 2-year open trial in Parkinson\u2019s disease patients with psychosis","volume":"44","author":"Factor","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib37","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/archinte.1985.00360050183031","article-title":"\u2018Drug Holiday\u2019 in the treatment of Parkinson\u2019s disease: a brief review","volume":"145","author":"Friedman","year":"1985","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib38","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1176\/ajp.135.6.669","article-title":"Levodopa-induced psychosis: a kindling phenomenon","volume":"135","author":"Moskowitz","year":"1978","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib39","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/BF00380972","article-title":"Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine","volume":"235","author":"Scholz","year":"1985","journal-title":"Eur Arch Psychiatry Neurol Sci"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib40","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/00002826-198710000-00011","article-title":"Idiopathic Parkinson disease in a chronic schizophrenic patient: long term treatment with clozapine and l-Dopa","volume":"10","author":"Friedman","year":"1987","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib41","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/00002826-200103000-00012","article-title":"Autopsy follow up of a patient with schizophrenia and presumed idiopathic Parkinson disease","volume":"24","author":"Friedman","year":"2001","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib42","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/0957154X07070335","article-title":"History of clozapine and its emergence in the US market: review and analysis","volume":"18","author":"Crilly","year":"2007","journal-title":"Hist Psychiatry"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib43","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1212\/01.wnl.0000215428.46057.3d","article-title":"Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"66","author":"Miyasaki","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib44","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/mds.870130302","article-title":"Clozapine use in Parkinson\u2019s disease: a retrospective analysisof a large multicentered clinical experience","volume":"13","author":"Trosch","year":"1998","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib45","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1212\/WNL.40.5.832","article-title":"Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis","volume":"40","author":"Wolters","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib46","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","article-title":"Clozapine in drug induced psychosis in Parkinson\u2019s disease: a randomised, placebo controlled study with open follow up","volume":"75","author":"Pollak","year":"2004","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib47","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/mds.22589","article-title":"Neuropsychiatric symptoms in Parkinson\u2019s disease","volume":"24","author":"Aarsland","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib48","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/mds.870090406","article-title":"Suppression of dyskinesia in advanced Parkinson\u2019s disease: moderate daily clozapine doses provide long-term dyskinesia reduction","volume":"9","author":"Bennetjr","year":"1994","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib49","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1600-0404.1986.tb03279.x","article-title":"Clozapine in the treatment of tremor","volume":"73","author":"Pakkenberg","year":"1986","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib50","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/mds.870050307","article-title":"Clozapine-responsive tremor in Parkinson\u2019s disease","volume":"5","author":"Friedman","year":"1990","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib51","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.parkreldis.2004.04.007","article-title":"Diabetes mellitus among parkinsonian patients treated chronically with clozapine","volume":"10","author":"Fernandez","year":"2004","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib52","first-page":"14","article-title":"Current use of clozapine in Parkinson\u2019s disease and related disorders","volume":"33","author":"Thomas","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib53","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S0140-6736(94)92511-9","article-title":"Risperidone for hallucinations in levodopa-treated Parkinson\u2019s disease patients","volume":"343","author":"Meco","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib54","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/1531-8257(200011)15:6<1230::AID-MDS1026>3.0.CO;2-9","article-title":"Risperidone in the treatment of dopamine-induced psychosis in Parkinson\u2019s disease: an open pilot trial","volume":"15","author":"Mohr","year":"2000","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib55","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1176\/jnp.9.4.594","article-title":"The use of risperidone for psychosis and agitation in demented patients with Parkinson\u2019s disease","volume":"9","author":"Workmanjr","year":"1997","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib56","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(94)92114-8","article-title":"Risperidone in Parkinson\u2019s disease","volume":"344","author":"Ford","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib57","first-page":"556","article-title":"Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson\u2019s disease and other akinetic-rigid syndromes","volume":"56","author":"Rich","year":"1995","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib58","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0140-6736(95)92307-1","article-title":"Neuroleptic sensitivity to risperidone in Lewy body dementia","volume":"346","author":"McKeith","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib59","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1176\/jnp.12.3.364","article-title":"Clozapine and risperidone in treatment of psychosis in Parkinson\u2019s disease","volume":"12","author":"Ellis","year":"2000","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib60","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1212\/WNL.52.4.782","article-title":"Neurologic side effects in neuroleptic na\u00efve patients treated with haloperidol or risperidone","volume":"52","author":"Rosebush","year":"1999","journal-title":"Neurol"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib61","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1212\/WNL.47.4.1085","article-title":"Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson\u2019s disease","volume":"47","author":"Wolters","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib62","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1212\/WNL.50.4.1195-a","article-title":"Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson\u2019s disease","volume":"50","author":"Friedman","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib63","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/mds.10217","article-title":"Olanzapine Treatment for Dopaminergic-hallucinations","volume":"17","author":"Ondo","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib64","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0006-3223(02)01392-6","article-title":"Olanzapine in the treatment of dopamimetic-induced psychosis in patient with Parkinson\u2019s disease","volume":"52","author":"Breier","year":"2002","journal-title":"Biol Psychol"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib65","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1212\/WNL.55.6.789","article-title":"Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients","volume":"55","author":"Goetz","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib66","first-page":"285","article-title":"Substituting clozapine for olanzapine in psychiatrically stable Parkinson\u2019s disease patients: results of an open label pilot study","volume":"21","author":"Friedman","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib67","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.wnf.0000136891.17006.ec","article-title":"Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis","volume":"27","author":"Morgante","year":"2004","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib68","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.10374","article-title":"Long term outcome of quetiapine use for psychosis among Parkinson patients","volume":"18","author":"Fernandez","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib69","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00415-005-0943-4","article-title":"Rabey. the effect of quetiapine in psychotic Parkinson patients with and without dementia. An open label study using a structured interview","volume":"253","author":"Prohorov","year":"2006","journal-title":"J Neurol"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib70","first-page":"661","article-title":"Quetiapine and ziprasidone in the treatment of the psychotic disorders in Parkinson\u2019s disease","volume":"39","author":"Lopez Del Val","year":"2004","journal-title":"Rev Neurol"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib71","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/01.WNF.0000236769.31279.19","article-title":"Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson\u2019s disease psychosis","volume":"29","author":"Merims","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib72","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/mds.20474","article-title":"Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson\u2019s disease","volume":"20","author":"Ondo","year":"2005","journal-title":"Mov Disord"},{"issue":"Suppl. 10","key":"10.1016\/j.parkreldis.2010.05.004_bib73","first-page":"S46","article-title":"The effect of quetiapine in Parkinson\u2019s disease (PD] psychotic patients: a double-blind labeled study of three months duration","volume":"20","author":"Rabey","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib74","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/NDT.S5335","article-title":"A randomized controlled trial of quetiapine for psychosis in Parkinson\u2019s disease","volume":"5","author":"Shotbolt","year":"2009","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib75","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.3109\/00207450903222758","article-title":"Quetiapine improves visual hallucinations in Parkinson\u2019s disease but not through normalization of sleep architecture: results of a double blind clinical-polysomnograph study","volume":"119","author":"Fernandez","year":"2009","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib76","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1212\/01.wnl.0000260060.60870.89","article-title":"Alzheimer Disease Cooperative Study Group. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism","volume":"68","author":"Kurlan","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib77","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/00002826-200401000-00003","article-title":"Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience","volume":"27","author":"Fernandez","year":"2004","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib78","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/mds.21091","article-title":"Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson\u2019s disease","volume":"21","author":"Friedman","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib79","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/mds.21025","article-title":"Aripiprazole associated with severe exacerbation of Parkinson\u2019s disease","volume":"21","author":"Wickremaratchi","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib80","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1176\/appi.ajp.2008.07061035","article-title":"A multiple center random double blind placebo controlled study of oral aripiprazole for treatment of adolescent schizophrenia","volume":"165","author":"Findling","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib81","doi-asserted-by":"crossref","unstructured":"Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, El-Sayeh HG, et\u00a0al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Schizophrenia Group. Issue 4, 2009","DOI":"10.1002\/14651858.CD006627.pub2"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib82","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/01.wnf.0000164297.91643.ff","article-title":"Use of ziprasidone in parkinsonian patients with psychosis","volume":"28","author":"Gomez-Esteban","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib83","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.clineuro.2006.07.003","article-title":"Treatment of drug-induced psychosis in Parkinson\u2019s disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing","volume":"109","author":"Schindehutte","year":"2007","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib84","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00131746-200103000-00009","article-title":"Ziprasidone: a new atypical antipsychotic","volume":"7","author":"Weiden","year":"2001","journal-title":"J Psychiatr Pract"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib85","doi-asserted-by":"crossref","unstructured":"Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Hunger H, Schwarz S et\u00a0al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Schizophrenia Group. Published in Issue 1, 2010.","DOI":"10.1002\/14651858.CD006628.pub2"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib86","first-page":"201","article-title":"Melperone in the treatment of iatrogenic psychosis in Parkinson\u2019s disease","volume":"11","author":"Barbato","year":"1996","journal-title":"Funct Neurol"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib87","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/npp.2009.176","article-title":"Pimavanserin, a serotonin (2A) receptor inverse agonist for the treatment of Parkinson\u2019s disease psychosis","volume":"35","author":"Meltzer","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib88","unstructured":"Friedman JH, Ravina B, Mills R, Burn D, Williams H, Revell S, et\u00a0al. A multi center, placebo controlled, double blind trial to examine the safety and efficacy of pimavanserin in the treatment of psychosis in Parkinson\u2019s disease. AAN abstract, Toronto, 2010"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib89","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/mds.21077","article-title":"Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson\u2019s disease","volume":"21","author":"Burn","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib90","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","article-title":"Rivastigmine for dementia associated with Parkinson\u2019s disease","volume":"351","author":"Emre","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib91","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3233\/JAD-2007-11412","article-title":"Rivastigmine in dementia associated with Parkinson\u2019s disease and Alzheimer\u2019s disease: similarities and differences","volume":"11","author":"Emre","year":"2007","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib92","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s100720200022","article-title":"Donepezil in the treatment of hallucinations and delusions in Parkinson\u2019s disease","volume":"23","author":"Fabbrini","year":"2002","journal-title":"Neurol Sci"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib93","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/gps.949","article-title":"Cognitive, psychiatric and motor response to galantamine in Parkinson\u2019s disease with dementia","volume":"18","author":"Aarsland","year":"2003","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib94","first-page":"276","article-title":"Parkinson\u2019s disease related visual hallucinations unresponsive to atypical antipsychotics treated with cholinesterase inhibitors: a case series","volume":"41","author":"Sobow","year":"2007","journal-title":"Neurol Neurochir Pol"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib95","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00002826-200203000-00009","article-title":"Successful use of donepezil for the treatment of psychotic symptoms in patient with Parkinson\u2019s disease","volume":"25","author":"Bergman","year":"2002","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib96","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/mds.1204","article-title":"Rivastigmine in the treatment of Parkinson psychosis and cognitive impairment: preliminary findings from an open trial","volume":"16","author":"Reading","year":"2001","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib97","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/0140-6736(93)90327-D","article-title":"Ondansetron for hallucinosis in advanced Parkinson\u2019s disease","volume":"341","author":"Zoldan","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib98","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1212\/WNL.45.7.1305","article-title":"Psychosis in advanced Parkinson\u2019s disease: treatment with ondansetron, a 5-HT3 receptor antagonist","volume":"45","author":"Zoldan","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib99","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1212\/WNL.47.6.1608-b","article-title":"Ondansetron treatment of l-dopa-induced psychosis","volume":"47","author":"Eichhorn","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib100","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1176\/jnp.2008.20.3.373","article-title":"Psychosis in a case of schizophrenia and Parkinson\u2019s disease","volume":"20","author":"Habermeyer","year":"2008","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib101","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0925-4927(98)00026-2","article-title":"Reduced striatal dopaminergfic innervation shown by IPT and SPECT in patients under neuroleptic treatment: need for levodopa therapy?","volume":"83","author":"Schwarz","year":"1998","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib102","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1440-1819.2006.01572.x","article-title":"Paranoid schizophrenia and idiopathic Parkinson\u2019s disease do coexist: a challenge for clinicians","volume":"60","author":"Winter","year":"2006","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib103","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00702-004-0208-x","article-title":"Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients","volume":"11","author":"Plotkin","year":"2005","journal-title":"J Neural Transm"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib104","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of Sudden cardiac death","volume":"360","author":"Ray","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib105","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1093\/brain\/awp166","article-title":"Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson\u2019s disease","volume":"132","author":"Manganelli","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2010.05.004_bib106","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/mds.22132","article-title":"Antipsychotic medication treatment for mild hallucinations in Parkinson\u2019s disease: positive impact on long-term worsening","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802010001112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802010001112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:11:34Z","timestamp":1761178294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802010001112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":106,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S1353802010001112"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2010.05.004","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Parkinson\u2019s disease psychosis 2010: A review article","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2010.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}